| Outcome Measures: |
Primary: The mean change in post-meal glucose levels from baseline at the end of observation period of up to 16 weeks, The primary outcome will be summarized separately in acarbose and metformin monotherapy treated patients having carbohydrates consumption (National Institute of Nutrition (NIN), India recommend50% to 60% of total calories from carbohydrates in balance diet : - Below NIN recommendation (\< 50%) - As per NIN recommendation (50% to 60%) - Above NIN recommendation (\> 60%), baseline and 16 weeks | Secondary: Mean change of HbA1c, Baseline and 16 weeks|Mean change of fasting blood glucose(FBG), Base line and 16 weeks|Mean change of low density lipoprotein cholesterol(LDL), baseline and 16 weeks|Mean change of high density lipoprotein cholesterol(HDL), Baseline and 16 weeks|Mean change of total cholesterol(TC), baseline and 16 weeks|Mean change of Body weight, baseline and 16 weeks|Mean change of triglyceride(TG), baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of postprandial blood glucose (PPBG), baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of HbA1c, baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of FBG, baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of LDL, baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of HDL, baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of TC, baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of TG, baseline and 16 weeks|Compare the mean change between acarbose and metformin arm of Body weight, baseline and 16 weeks|Change in gastrointestinal tolerability to therapy from post baseline visit to the end of observation period of up to 16 weeks, baseline and 16 weeks|Incidence rate of adverse drug reactions in acarbose and metformin treated groups during 16 weeks observation period, 16 weeks
|
